Navigation Links
Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
Date:10/24/2011

PINE BROOK, N.J., Oct. 24, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is initiating a new clinical study to further demonstrate the safety of Anthim (ETI-204), the company's anti-toxin in late-stage development for prevention of disease and death from exposure to inhaled anthrax. The company also announced it has successfully manufactured Anthim at commercial scale. Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack.

(Logo: http://photos.prnewswire.com/prnh/20090420/NY01624LOGO)

The double blind, placebo-controlled dose-escalating study will include a total of 108 healthy human subjects and is designed to collect additional safety and pharmacokinetic (PK) data on Anthim.

"Our development timeline for Anthim is right on track, and this additional safety and PK data will further prove Anthim's utility as a strong candidate for addition to the Strategic National Stockpile," said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. "Anthim is demonstrating the potential to deliver significant therapeutic benefit to Americans infected with anthrax in a bioterrorism emergency."

Dr. Posillico will be presenting an update on Anthim's development program at the 10th Annual BIO Investor Forum in San Francisco on October 26.

"We have successfully manufactured Anthim at commercial scale, and look forward to finalizing our commercial production process to ensure the large-scale capacity needed to deliver high quality, consistent quantities of Anthim for the long term," added James Porter, Vice President of Development and Manufacturing at Elusys.

Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis and remains one of the nation's top biowarfare threats. Inhaled anthrax is usually fatal, despite treatment with antibiotics, unless the patient is treated soon after exposure.

If all activities in the Anthim development program are completed to the U.S. Food and Drug Administration's (FDA) satisfaction, the federal government could purchase Anthim for the Strategic National Stockpile (SNS) under Project BioShield. Project BioShield was established in 2004 to provide much needed funding to procure important countermeasures to protect the American public in the event of a biowarfare attack.

Elusys has the potential to receive funding totaling up to $143 million for a base plus four option year contract, awarded December 2009, for development of Anthim for treatment of symptomatic patients. The company also received the first U.S. government contract, awarded September 2011, for a base plus three option year contract for $68.9 million, to develop an anthrax anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection (IM).

About Anthim

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalational anthrax following a biowarfare attack.

Anthim has been extensively tested for efficacy and safety in animals and safety in human volunteers. It shows excellent potential as an effective, life-saving therapeutic for the treatment of people infected by or exposed to anthrax spores. A single dose of Anthim consistently protects 70% to 100% of anthrax-infected animals from death.

This project is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201000026C, the National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), and the Department of Health and Human Services (HHS), under Contract No. HHSN272200700035C.

About Elusys Therapeutics, Inc.

Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Elusys has been engaged in development of biodefense countermeasures since 2000. The company has established experience in government contract management and to date has received multiple grants and has the potential to receive funding totaling up to $246 million in government funding. Anthim, a highly effective, anthrax anti-toxin, is in late-stage development, and is a strong candidate for future procurement into the Strategic National Stockpile. For more information, please visit www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection
2. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
3. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
4. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
5. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
6. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
7. CareFusion Initiates Class I Recall of EnVe Ventilators
8. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
9. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
10. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
11. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , Jan. 16, 2017 CBDRx, the ... large amounts of phyto-nutrient rich hemp extract to Veteran,s ... donation of their proprietary hemp extract to Veteran,s groups ... the best hemp company in the world and through ... most nutritious, full spectrum phyto-nutrient rich hemp extract available. ...
(Date:1/13/2017)... Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), today announced that ... at Eli Lilly & Company, has been appointed to InMed ... years of senior financial and executive leadership to InMed,s Board ... ... leadership position in financial and business expertise with one of ...
(Date:1/13/2017)... MURRIETA, Calif. , Jan. 13, 2017  Alfalfa, cattle, ... COPAN Diagnostic,s new environmental sampling film , which emphasizes the ... video, released today, highlights how COPAN,s ... product that simplifies the surface sampling process in the wake ... . In addition, COPAN is expanding ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company Incentive ... the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide BraunAbility a ... vehicles. With this new incentive plan, BraunAbility plans to continue their tradition of ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: January 9, ... , Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... first-quality education and high-level training standards to an international multidisciplinary group of healthcare ... problems. As a way to further its mission at the grassroots level, iaedp ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. Ben Amini ... 3-D scanning device which is capable of taking digital impressions of teeth and gums. ... as CAD CAM restorations , in terms of speed, efficiency and patient comfort. ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s VAR ... field of midmarket financial software. , Members of the VAR Stars were selected based ... on revenue and those firms chosen represent a wide range of size and many ...
Breaking Medicine News(10 mins):